


文檔簡介
1、Product Data SheetYO-01027Cat. No.: HY-13526CAS No.: 209984-56-5分式: CHFNO分量: 463.48作靶點: Notch; -secretase作通路: Neuronal Signaling; Stem Cell/Wnt儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO : 33 mg/mL (71.20 mM)H2O : 0.1 mg/mL (insoluble)* means soluble, but sat
2、uration unknown.SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 2.1576 mL 10.7880 mL 21.5759 mL5 mM 0.4315 mL 2.1576 mL 4.3152 mL10 mM 0.2158 mL 1.0788 mL 2.1576 mL請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;旦配成溶液,請分裝保存,避免反復凍融造成的產品失效。儲備液的保存式和期限:-80C, 6 months; -20C, 1 month。-80C 儲存時,請在 6 個內使,-20C 儲存時,請在 1 個內使。體內實驗
3、請根據您的實驗動物和給藥式選擇適當的溶解案。以下溶解案都請先按照 In Vitro 式配制澄清的儲備液,再依次添加助溶劑:為保證實驗結果的可靠性,澄 的儲備液可以根據儲存條件,適當保存;體內實驗的作液,建議您現現配,當天使; 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占;如在配制過程中出現沉淀、析出現象,可以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.39 mM); Suspended solution; Need ultrasonic此案可獲
4、得 2.5 mg/mL (5.39 mM) 的均勻懸濁液,懸濁液可于服和腹腔注射。以 1 mL 作液為例,取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 400 L PEG300 中,混合均勻;向上述體系中加50 L Tween-80,混合均勻;然后繼續加 450 L 理鹽定容 1 mL。2. 請依序添加每種溶劑: 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (5.39 mM); Suspended solution; Need ultrasonicPage 1 of 2 www.MedChemE此案可獲得
5、 2.5 mg/mL (5.39 mM) 的均勻懸濁液,懸濁液可于服和腹腔注射。以 1 mL 作液為例,取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 900 L 20% 的 SBE-CD 理鹽溶液中,混合均勻。3. 請依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (5.39 mM); Clear solution此案可獲得 2.5 mg/mL (5.39 mM,飽和度未知) 的澄 溶液,此案不適于實驗周 期在半個以上的實驗。以 1 mL 作液為例,取 100 L 25.0 mg/mL 的澄 DMSO 儲備液加到 9
6、00 L 油中,混合均勻。BIOLOGICAL ACTIVITY物活性 YO-01027 (Dibenzazepine; DBZ)效的 -分泌酶抑制劑,裂解 Notch 和 APPL 的 IC50 分別為 2.92 和 2.64 nM。IC & Target IC50: 2.920.22 (Notch), 2.640.30 (APPL) nM1體外研究 Increasing concentrations of DBZ administered to APPL- or Notch-expressing cells leads to the progressiveaccumulation of A
7、PPL CTF fragments and a decrease in NICD production in a strictly dose-dependent manner1. Themolecular targets of CE and DBZ are the N-terminal fragment of presenilin 1 within the -secretase complex2.體內研究 DBZ blocks activated Notch1 signaling in abdominal aortic aneurysm (AAA) tissue from both Ang I
8、I-infused Apo E-/-mice and human undergoing AAA repair. DBZ markedly prevents Ang II-stimulated accumulation of macrophages and CD4+ T cells, and ERK-mediated angiogenesis, simultaneously reverses Th2 response, in vivo3. Administration ofDBZ markedly attenuates renal fibrosis and expression of fibro
9、tic markers, including collagen 11/31, fibronectin,and -smoothmuscle actin. DBZ significantly inhibits ureteral obstruction -induced expression of transforming growthfactor (TGF)- , phosphorylated Smad 2, and Smad 34.PROTOCOLCell Assay 1 DBZ (0.1, 1, 2.5, 5, 7.5, 10, 25, 50, 100, 250 nM) are added t
10、o the S2 cell medium upon induction of Notch or APPLexpression, 6 h before protein harvesting. For each sample, the same inhibitor is also included at the correspondingconcentration in the lysis buffer for protein extraction and immunoblot analysis1.MCE has not independently confirmed the accuracy o
11、f these methods. They are for reference only.Animal Mice: Male wild-type (WT) C57BL/6J and Apo E-/- mice are used in the study. Ang II-treated mice are received anAdministration 3 intraperitoneal injection of either saline vehicle or -secretase inhibitor, dibenzazepine (DBZ) (1 mg/kg/d, dissolved in
12、saline) 1 day before mini-pump implantation, and the treatment continued daily for 4 weeks. The blood pressure ismeasured in conscious mice using a computerized tail-cuff system. All mice are anesthetized. The aortic tissues areremoved and prepared for further histological and molecular analysis3.MC
13、E has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Groth C, et al. Pharmacological analysis of Drosophila melanogaster gamma-secretase with respect to differential proteolysis of Notch and APP. MolPharmacol. 2010 Apr;77(4):567-74.2. Fuwa H, et a
14、l. Divergent synthesis of multifunctional molecular probes to elucidate the enzyme specificity of dipeptidic gamma-secretase inhibitors. ACSChem Biol. 2007 Jun 15;2(6):408-18.Page 2 of 3 www.MedChemE3. Zheng YH, et al. Notch -secretase inhibitor dibenzazepine attenuates angiotensin II-induced abdominal aortic aneurysm in ApoE knockout mice bymultiple mechanisms. PLoS One. 2013 Dec 16;8(12):e83310.4. Xiao Z, et al. The Notch -secretase inhibitor ameliorates kidney fibrosis via inhibition of TGF-/Smad2/3 signaling pathway activation. Int J Biochem CellBiol. 2014 Oct;55:65-7
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經權益所有人同意不得將文件中的內容挪作商業或盈利用途。
- 5. 人人文庫網僅提供信息存儲空間,僅對用戶上傳內容的表現方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
- 6. 下載文件中如有侵權或不適當內容,請與我們聯系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- GB/T 45820-2025石油煉化裝置用透平壓縮機
- TD/T 1043.2-2013暗管改良鹽堿地技術規程第2部分:規劃設計與施工
- 2025年伊索寓言讀后心得(8篇)
- 2025年初升高暑期數學講義專題01 數與式的計算重難點突破(含答案)
- 剝奪政治權利98課件
- 2025-2026年高校教師資格證之《高等教育法規》通關題庫附參考答案詳解(能力提升)
- 2025年江西省高速公路投資集團有限責任公司招聘筆試備考題庫附答案詳解(黃金題型)
- 2025年Z世代消費趨勢下新消費品牌品牌戰略研究報告
- 2025年K2學校STEM課程教學模式改革與效果分析報告
- 第三單元+明清時期(至鴉片戰爭前):統一多民族封建國家的鞏固與發展+綜合檢測課件-2024-2025學年度下學期七年級歷史期末復習
- 精裝分包勞務合同協議書
- 2025-2030中國酸奶冰淇淋市場需求前景預測及投資效益盈利性研究報告
- 2025年高考英語應用文第09講 讀后續寫分話題萬能結尾滿分句(講義)
- 2025年四年級下冊美術期末測試題附答案
- 圖像編輯基礎Photoshop試題及答案
- 新媒體國企面試題及答案
- 寶寶改姓夫妻協議書
- 宣城汽車精密零部件項目商業計劃書
- 2021入河(海)排污口三級排查技術指南
- 央企華潤集團杭州片區年度品牌傳播策略案
- 2024年深圳市中考歷史試卷真題(含答案解析)
評論
0/150
提交評論